Northern Trust’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-962,548
| Closed | -$17.3M | – | 4370 |
|
|
2020
Q2 | $17.3M | Sell |
962,548
-139,022
| -13% | -$1.93M | ﹤0.01% | 1742 |
|
|
2020
Q1 | $7.85M | Buy |
1,101,570
+126,705
| +13% | +$1.58M | ﹤0.01% | 2030 |
|
|
2019
Q4 | $23.3M | Buy |
974,865
+7,326
| +0.8% | +$202K | 0.01% | 1617 |
|
|
2019
Q3 | $25.9M | Buy |
967,539
+125,509
| +15% | +$3.52M | 0.01% | 1472 |
|
|
2019
Q2 | $22.8M | Buy |
842,030
+11,208
| +1% | +$351K | 0.01% | 1591 |
|
|
2019
Q1 | $28.8M | Buy |
830,822
+26,943
| +3% | +$777K | 0.01% | 1393 |
|
|
2018
Q4 | $15.7M | Sell |
803,879
-21,505
| -3% | -$442K | ﹤0.01% | 1768 |
|
|
2018
Q3 | $22M | Buy |
825,384
+5,816
| +0.7% | +$190K | 0.01% | 1723 |
|
|
2018
Q2 | $31M | Buy |
819,568
+81,618
| +11% | +$3.12M | 0.01% | 1415 |
|
|
2018
Q1 | $24.1M | Buy |
737,950
+3,880
| +0.5% | +$170K | 0.01% | 1539 |
|
|
2017
Q4 | $35.7M | Buy |
734,070
+46,085
| +7% | +$2.33M | 0.01% | 1269 |
|
|
2017
Q3 | $37.2M | Buy |
687,985
+51,987
| +8% | +$3.05M | 0.01% | 1203 |
|
|
2017
Q2 | $35.7M | Buy |
635,998
+19,719
| +3% | +$790K | 0.01% | 1209 |
|
|
2017
Q1 | $24.2M | Buy |
616,279
+13,938
| +2% | +$444K | 0.01% | 1509 |
|
|
2016
Q4 | $13.5M | Buy |
602,341
+5,719
| +1% | +$112K | ﹤0.01% | 1887 |
|
|
2016
Q3 | $13.6M | Sell |
596,622
-4,211
| -0.7% | -$98.8K | ﹤0.01% | 1861 |
|
|
2016
Q2 | $14.2M | Sell |
600,833
-2,767
| -0.5% | -$68.3K | ﹤0.01% | 1787 |
|
|
2016
Q1 | $12.6M | Buy |
603,600
+2,714
| +0.5% | +$86.1K | ﹤0.01% | 1811 |
|
|
2015
Q4 | $30.9M | Buy |
600,886
+55,746
| +10% | +$2.7M | 0.01% | 1152 |
|
|
2015
Q3 | $23.2M | Sell |
545,140
-1,980
| -0.4% | -$95.5K | 0.01% | 1378 |
|
|
2015
Q2 | $24.9M | Buy |
547,120
+38,401
| +8% | +$1.54M | 0.01% | 1416 |
|
|
2015
Q1 | $19.3M | Buy |
508,719
+16,060
| +3% | +$552K | 0.01% | 1604 |
|
|
2014
Q4 | $14M | Buy |
492,659
+52,225
| +12% | +$1.45M | ﹤0.01% | 1808 |
|
|
2014
Q3 | $11.1M | Buy |
440,434
+275,348
| +167% | +$7.25M | ﹤0.01% | 1958 |
|
|
2014
Q2 | $4.82M | Sell |
165,086
-11,698
| -7% | -$283K | ﹤0.01% | 2537 |
|
|
2014
Q1 | $4.58M | Buy |
176,784
+32,526
| +23% | +$868K | ﹤0.01% | 2619 |
|
|
2013
Q4 | $3.71M | Buy |
144,258
+18,057
| +14% | +$439K | ﹤0.01% | 2761 |
|
|
2013
Q3 | $3.38M | Buy |
126,201
+73,941
| +141% | +$1.76M | ﹤0.01% | 2765 |
|
|
2013
Q2 | $1.28M | Buy |
+52,260
| New | +$1.04M | ﹤0.01% | 3197 |
|
Northern Trust's PTLA Position: Q3 2020 in Review
Northern Trust sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 962,548 shares — an estimated $17.3M sold.
Northern Trust first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $37.2M in Q3 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Northern Trust reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Northern Trust sold 962,548 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $17.3M.
- Northern Trust first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Northern Trust's Portola Pharmaceuticals, Inc. position peaked at $37.2M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Northern Trust's 13F filing for Q3 2020, filed 16 Nov 2020.